This session focused on the role of artificial intelligence in reshaping clinical trials. Speakers demonstrated how AI tools had begun to streamline trial design, accelerate patient recruitment, and improve endpoint assessment. Case examples illustrated how these technologies were already reducing inefficiencies across the trial lifecycle.

The panel also addressed challenges such as data quality, validation, and regulatory acceptance. While AI was shown to hold transformative potential, the discussion emphasized the need for careful integration to ensure scientific credibility and patient safety.

Transforming clinical trials with AI

Managing Director, AKT Health, Chief Investment Officer (CIO) AKT Capital | AKT Health Inc.

David A Hall

1

64

705

4.1

Sessions Taken

97

4.5